Shots: The P-III ENVISION study involves assessing of Givosiran vs PBO in patients with acute hepatic porphyria (AHP) ENVISION study results:74% mean reduction of annualized rate of porphyria attacks; 90% […]readmore
Tags : ENVISION
Shots: The P-III ENVISION study involves assessing of Givosiran vs PBO in 94 patients with AHP including patients with acute intermittent porphyria (AIP) across 18 countries in ratio 1:1 The […]readmore